Navigation Links
GenScript Biotech to Host Global Forum on Cell and Gene Therapy and the Booming China Market During JPM Week
Date:1/10/2020

GenScript Biotech Corp., one of the leading biotechnology companies in China, today announced its inaugural GenScript Biotech Global Forum on Jan. 14 in San Francisco, coinciding with the JP Morgan Healthcare Conference week. The Forum, exploring the theme "Cell and Gene Therapy and the Booming China Market," will feature gene and cell therapy leaders in industry, academia and the investment community and is expected to draw several hundred attendees.

"Advancements in cell and gene therapy have attracted global attention in recent years, as the promise of bringing life-changing treatments to cancer patients and others comes closer to reality," said Frank Zhang, PhD., founder and CEO of GenScript. "GenScript's Global Forum aims to foster closer collaborations among scientists, regulators, and industry, not just in the booming Chinese market but around the globe. We hope that by working together we can advance the industry and accelerate drug development."

GenScript's Global Forum will take place from 1:30 p.m. to 5:30 p.m. at the Grand Hyatt San Francisco. Highlights of the agenda include:

  • Keynote by former FDA Commissioner Scott Gottlieb, M.D.
  • Panel discussion on global progress in cell and gene therapy with Legend Biotech, Kite, Ziopharm Oncology, GE Healthcare Life Sciences, Johnson & Johnson Innovation Asia Pacific and CARspen Therapeutics
  • Panel discussion on technology transfer with Biomedica, Genethon, Genscript, JW Therapeutics, and Fosun Kite
  • Panel discussion on the capital potential of China's cell therapy industry with Loncar Investments, GenScript Biotech, Lake Bleu Capital and Lilly Asia Ventures
  • Panel discussion on the global cell therapy regulatory environment

For more information about the Forum and to register for the event, please visit https://www.genscript.com/biotech-global-forum-2020.html.

About GenScript Biotechnology

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. GenScript’s businesses encompass four major categories based on its leading gene synthesis technology, including operation as a Life Science CRO, enzyme and synthetic biology products, biologics development and manufacturing, as well as cell therapy.

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and the Asia Pacific. Today, over 300,000 customers from over 160 countries and regions around the world have used GenScript’s premier, convenient, and reliable products and services.

GenScript currently has more than 2900 employees globally, 34% of whom hold master’s and/or Ph.D. degrees. In addition, GenScript has a number of leading commercial technologies, including more than 100 patents and over 270 patent applications. As of June 2019, GenScript's products and services have been cited by 40,300 scientific papers worldwide.

GenScript is committed to striving towards its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

For more information, please visit https://www.genscript.com/

Contact Details

Frank Zhang

GenScript

860 Centennial Ave.
Piscataway, NJ 08854

USA

1-877-436-7274

Source: GenScript Biotech Corp.

Read the full story at https://www.prweb.com/releases/genscript_biotech_to_host_global_forum_on_cell_and_gene_therapy_and_the_booming_china_market_during_jpm_week/prweb16824380.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz
2. Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz
3. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
4. GIN Introduces Advanced Robotics and Dispensing Technology at BVS La Jolla Biotech Day
5. The BioVoyage Institute Now Offering Hands-On Training Programs For Biotechnology Products & Applications
6. Riveting NY Times Bestselling Biotech Thriller, WIRED, Now Only $5.95 for Kindle Owners
7. Animal Biotechnology 2013 Market Report
8. The BioVoyage Institute is seeking the help of corporations, organizations, institutions, communities and individuals to help with bioscience and biotechnology education
9. XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK
10. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the March 2013 Digital Edition Now Available Online and in the App Store
11. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2020)... CITY, and LA JOLLA, Calif. (PRWEB) , ... March 31, 2020 ... ... tools, and La Jolla Institute for Immunology (LJI), announced today that they will use ... allowing CoVIC to move therapeutic candidates to the clinic as early as this summer. ...
(Date:3/27/2020)... ... March 25, 2020 , ... ... histopathology laboratory located centrally in the midwest for high-quality, quick-turn, board-certified reporting. ... a highly motivated, independent, professional team that is focused on incredible quality, ...
(Date:3/19/2020)... ... March 17, 2020 , ... ... collaboration agreement with pioneering gene circuit company Senti Biosciences, Inc. (Senti) to ... and other solid tumor indications. The collaboration will leverage RoosterBio’s human mesenchymal ...
(Date:3/13/2020)... ... March 12, 2020 , ... Today, DuPont Nutrition ... Research Center (APC), a pioneer in the field of microbiome science, which focuses ... role in human health, based at University College Cork and Teagasc Moorepark. , ...
Breaking Biology Technology:
(Date:4/1/2020)... ... 31, 2020 , ... Flagship Biosciences, providers of expert tissue ... team as Vice President Clinical Diagnostics. Geoff brings 25 years of experience in ... will lead the creation and implementation of diagnostic tissue tests utilizing Flagship’s unique ...
(Date:3/20/2020)... Conn. (PRWEB) , ... March 20, 2020 , ... ... the development of human embryonic stem cell (ESC) derived mesenchymal stem cells (hES-MSC), ... T-MSC) for the treatment of neurological, autoimmune, and rare orphan diseases, today announced ...
(Date:3/13/2020)... ... March 13, 2020 , ... ... Vivorte Inc. to be the exclusive distributor of the Louisville-based company’s orthobiologics portfolio. ... medical education expertise to distribute Vivorte’s calcium phosphate-based bone allograft (Trabexus) and calcium ...
Breaking Biology News(10 mins):